Pacira | PCRX - Interest Expense On Debt

Stock Price
22.64
Daily Change
-0.89 -3.78%
Monthly
-5.11%
Yearly
-12.45%
Q2 Forecast
22.18

Pacira reported $3.7M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Assertio Holdings USD 758K 1000 Jun/2024
Astellas Pharma JPY 3.91B 320M Mar/2025
Bristol-Myers Squibb USD 411M 21M Mar/2026
Cara Therapeutics -89.64M 128.67M Dec/2025
Coherus Biosciences USD 2.25M 76K Dec/2025
Heron Therapeutics USD 600K 100K Dec/2024
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
J&J USD 43M 25M Mar/2026
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Novo Nordisk DKK 1.53B 3.43B Sep/2025
Omeros USD 4.05M 5.16M Sep/2024
Pacira USD 3.7M 193K Mar/2026
Perrigo USD 7.98B 7.94B Mar/2026
Pfizer USD 671M 40M Mar/2026
Supernus Pharmaceuticals USD 910K 278K Jun/2023
Teva Pharmaceutical Industries USD 216M 4M Mar/2026
Xeris Pharmaceuticals USD 7.15M 115K Dec/2025
Xoma USD 3.4M 150K Jun/2024
Zoetis USD 62M 5M Mar/2026